

Product Data Sheet

Product Name: CPYPP
Cat. No.: GC50065

Chemical Properties

Cas. No. 310460-39-0

SMILES O=C(N(C3=CC=CC=C3)NC2=O)/C2=C\C=C\C1=C(Cl)C=CC=C1


Formula $C_{18}H_{13}ClN_2O_2$ M.Wt 324.76

Solubility DMSO: 50 mM Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Protocol

Cell experiment [1]:

Cell lines Spleen cells of BALB/c mice

Spleen cells of BALB/c mice (1×10^7 /ml) were incubated in RPMI1640 medium Preparation Method supplemented with 0.5% BSA or 10% FCS in the presence or absence of 100 μ M CPYPP. 1 or 5 hr of incubation at 37°C.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Reaction Conditions 100 μ M for 1 hour or 5 hours

Applications CPYPP was nontoxic when applied to spleen cells at 100 μ M .

Animal experiment [2]:

Animal models male C57BL/6J mice

Preparation Method Mice were randomized into four groups (n = 6): the saline + vehicle group, LPS + vehicle group, saline + CPYPP group, and LPS + CPYPP group. ALI was induced by intraperitoneal (i.p.) injection of LPS (10 mg/kg) body weight; The mice in the LPS + vehicle and LPS + CPYPP groups received CPYPP (250 mg/kg) or an equivalent volume of vehicle via i.p. injection 10 min after LPS administration. The mice in the saline + vehicle and saline + CPYPP groups received CPYPP (250 mg/kg) or an equivalent volume of vehicle via i.p. injection 10 min after saline administration.

Dosage form Intraperitoneal injection, 250 mg/kg

Applications CPYPP-treated mice had decreased lung injury scores compared with vehicle-treated mice. Furthermore, CPYPP-treated mice exhibited significantly decreased MPO activity and W/D ratios, which indicated decreased pulmonary edema.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

- [1]: Nishikimi A, Uruno T, Duan X, Cao Q, Okamura Y, Saitoh T, et al. Blockade of inflammatory responses by a small-molecule inhibitor of the Rac activator DOCK2. *Chem Biol* 2012;19:488-97.
- [2]: Xu, X., Su, Y., Wu, K., Pan, F. & Wang, A. DOCK2 contributes to endotoxemia-induced acute lung injury in mice by activating proinflammatory macrophages. *Biochem. Pharmacol.* 181, 114399 (2021).

Background

CPYPP bound to DOCK2 DHR-2 domain (DOCK2^{DHR-2}) in a reversible manner and inhibited its catalytic activity^[1].

CPYPP inhibited the guanine nucleotide exchange factor (GEF) activity of DOCK2DHR-2 for Rac1 in a dose-dependent manner, with a half-maximal inhibitory concentration (IC₅₀) of 22.8 ± 2.4 μM. This inhibitory activity was independent on length of preincubation time, ranging from 2 min to 30 min. In addition, CPYPP was nontoxic when applied to spleen cells or thymoma cells (BW5147α-β-) at 100 μM for 3 hr or 3 days, respectively^[1]. Pre-treatment of human neutrophils with CPYPP, a small molecule inhibitor of the DHR-2 domain of DOCK proteins and thus of the Rac GEF activity of human DOCK2 and DOCK5, significantly impaired neutrophil chemotaxis and ROS production^[2].

CPYPP effectively decreased the secretion and gene expression of TNF-α, IL-1β and IL-6 in the lungs, suggested effects of DOCK2 on endotoxemia-induced inflammatory responses in mice. CPYPP remarkably inhibited the infiltration of total cells, macrophages and neutrophils into the bronchoalveolar lavage fluid^[3]. A research found out that a joint usage of both CPYPP and C25-140 revealed a better consequence compared to monotherapy against hepatic I/R injury^[4].

References:

- [1]. Nishikimi A, Uruno T, Duan X, Cao Q, Okamura Y, Saitoh T, et al. Blockade of inflammatory responses by a small-molecule inhibitor of the Rac activator DOCK2. *Chem Biol* 2012;19:488-97.
- [2]. Moens, L., Gouwy, M., Bosch, B. et al. 2019. Human DOCK2 deficiency: report of a novel mutation and evidence for neutrophil dysfunction. *J. Clin. Immunol.* 39:298.
- [3]. Xu, X., Su, Y., Wu, K., Pan, F. & Wang, A. DOCK2 contributes to endotoxemia-induced acute

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

lung injury in mice by activating proinflammatory macrophages. Biochem. Pharmacol. 181, 114399 (2021).

[4]. Zuotian Huang, Junliang Pua, Yunhai Luo, et al. FAM49B, restrained by miR-22, relieved hepatic ischemia/reperfusion injury by inhibiting TRAF6/IKK signaling pathway in a Rac1-dependent manner. Molecular Immunology.143, 2022, 135-146.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA